Steminov
Biotech developing WhartSep stem cell therapy for severe pneumonia and a 3D manufacturing platform for MSCs, offered to drug developers
Highlights
- New on EvolcAdded 2026-11-11
About Steminov
StemInov is a French biotechnology company developing a proprietary 3D bioproduction platform for mesenchymal stem cells (MSCs), designed to deliver off-the-shelf allogeneic therapies at clinical scale. Its lead candidate, WhartSep®, is a Wharton's jelly MSC therapy targeting severe community-acquired pneumonia associated with ARDS and sepsis, described as Phase IIa-ready by Q1-2027.
The company plans to monetise its platform through R&D collaborations, CDMO partnerships to manufacture Wharton's jelly MSCs for third-party developers, and out-licensing of its development in additional indications. Its target partners are cell therapy and drug developers.
StemInov was founded in 2019 as a spin-off of the Nancy Regional University Hospital (CHRU de Nancy) and the University of Lorraine, and is based in Vandœuvre-lès-Nancy, France. The company reports two patents covering its platform.
Product: WhartSep®, a Wharton's jelly mesenchymal stem cell therapy, and a 3D bioproduction platform for MSC manufacturing.
Jobs at Steminov
Leadership
- Danièle BENSOUSSAN · Scientific founderSource: company website
- Julie HUTIN · CEO founderSource: company website
More biotech & pharma companies
Stimunity
Develops STING-pathway drugs to stimulate immune responses against cancer and infectious diseasesNew on EvolcStrainchem
Green chemistry synthesis and process-development services for organizations working with small molecules and peptidesNew on EvolcSubstipharm
Develops and supplies medicines and vaccines for pharmaceutical partners and patients worldwideSuperbranche
Magnetic nanoparticles for focused-hyperthermia cancer treatment and imaging, developed for research and biotech partnersNew on EvolcSynaxys
Preclinical neuroscience assays and human neuronal models for pharmaceutical and research organizationsNew on EvolcSyndivia
Develops antibody-drug conjugate candidates and hinge-specific conjugation technology for cancer treatmentNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Backend
- PHPHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-powered-by
- Response headerx-powered-by
- Response headerx-powered-by
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Website resourcedeclared script/iframe or software asset
Forms
- Gravity FormsHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- ApacheHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.